STOCK TITAN

[8-K] SANUWAVE Health, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Insider activity: Director Edward J. Rapp filed a Form 4 disclosing two equity grants made on 07/10/2025. He acquired 62,377 Restricted Stock Units (RSUs) that will vest on the earlier of 07/10/2026 or the eve of the 2026 annual meeting, and received an additional 1,601 RSUs in lieu of his Q2-2025 cash retainer for chairing the Audit Committee, which vested immediately. All shares were acquired at a cost of $0.

Post-transaction ownership: Rapp now holds 121,894 common shares directly (including 62,377 unvested RSUs) and 21,172 shares indirectly through a trust, bringing his total beneficial stake to 143,066 shares.

Key context:

  • The grants are part of routine director compensation and were not open-market purchases.
  • Vesting of the larger RSU block requires Rapp’s continued board service through 2026, signalling expected tenure stability.
  • No derivative securities were reported, and no dispositions occurred.

Attività degli insider: Il direttore Edward J. Rapp ha presentato un Modulo 4 per comunicare due assegnazioni di azioni effettuate il 10/07/2025. Ha acquisito 62.377 Unità Azionarie Vincolate (RSU) che matureranno alla data anticipata tra il 10/07/2026 o la vigilia dell'assemblea annuale del 2026, e ha ricevuto ulteriori 1.601 RSU in sostituzione del compenso in contanti del secondo trimestre 2025 per la presidenza del Comitato di Revisione, che sono maturate immediatamente. Tutte le azioni sono state acquisite a costo zero.

Possesso post-transazione: Rapp detiene ora 121.894 azioni ordinarie direttamente (incluse 62.377 RSU non ancora maturate) e 21.172 azioni indirettamente tramite un trust, portando la sua partecipazione totale effettiva a 143.066 azioni.

Contesto chiave:

  • Le assegnazioni fanno parte della normale retribuzione dei direttori e non sono acquisti sul mercato aperto.
  • La maturazione del blocco più grande di RSU richiede che Rapp rimanga nel consiglio fino al 2026, indicando una stabilità prevista nella sua permanenza.
  • Non sono stati segnalati strumenti derivati né sono avvenute cessioni.

Actividad de los insiders: El director Edward J. Rapp presentó un Formulario 4 informando sobre dos concesiones de acciones realizadas el 10/07/2025. Adquirió 62,377 Unidades de Acciones Restringidas (RSU) que se consolidarán en la fecha que ocurra primero entre el 10/07/2026 o la víspera de la junta anual de 2026, y recibió 1,601 RSU adicionales en lugar de su remuneración en efectivo del segundo trimestre de 2025 por presidir el Comité de Auditoría, las cuales se consolidaron inmediatamente. Todas las acciones se adquirieron sin costo alguno.

Propiedad después de la transacción: Rapp ahora posee 121,894 acciones comunes directamente (incluyendo 62,377 RSU no consolidadas) y 21,172 acciones indirectamente a través de un fideicomiso, sumando una participación total beneficiaria de 143,066 acciones.

Contexto clave:

  • Las concesiones forman parte de la compensación habitual para directores y no fueron compras en el mercado abierto.
  • La consolidación del bloque mayor de RSU requiere que Rapp continúe en la junta hasta 2026, lo que indica estabilidad esperada en su permanencia.
  • No se reportaron valores derivados ni se realizaron disposiciones.

내부자 활동: 이사 Edward J. Rapp는 2025년 7월 10일에 이루어진 두 건의 주식 부여를 공개하는 Form 4를 제출했습니다. 그는 62,377개의 제한 주식 단위(RSU)를 취득했으며, 이는 2026년 7월 10일 또는 2026년 연례 회의 전날 중 빠른 시점에 베스팅됩니다. 또한 감사위원회 의장으로서 2025년 2분기 현금 보수 대신 추가로 1,601 RSU를 받았으며 이 주식은 즉시 베스팅되었습니다. 모든 주식은 비용 없이 취득되었습니다.

거래 후 소유 현황: Rapp는 현재 직접 보유한 보통주 121,894주(미베스팅 RSU 62,377주 포함)와 신탁을 통해 간접 보유한 21,172주를 보유하여 총 실질 지분이 143,066주입니다.

주요 배경:

  • 이번 부여는 이사 보수의 일환으로 시장에서 매입한 것이 아닙니다.
  • 대규모 RSU 블록의 베스팅은 Rapp가 2026년까지 이사회에 계속 참여해야 하므로 그의 임기 안정성을 시사합니다.
  • 파생 증권 보고는 없었고, 주식 처분도 없었습니다.

Activité des initiés : Le directeur Edward J. Rapp a déposé un formulaire 4 révélant deux attributions d’actions réalisées le 10/07/2025. Il a acquis 62 377 unités d’actions restreintes (RSU) qui seront acquises à la date la plus proche entre le 10/07/2026 ou la veille de l’assemblée générale annuelle 2026, et a reçu 1 601 RSU supplémentaires en lieu et place de sa rémunération en espèces du deuxième trimestre 2025 pour la présidence du comité d’audit, lesquelles ont été acquises immédiatement. Toutes les actions ont été obtenues sans coût.

Possession après la transaction : Rapp détient désormais 121 894 actions ordinaires directement (dont 62 377 RSU non acquises) et 21 172 actions indirectement par le biais d’une fiducie, portant sa participation bénéficiaire totale à 143 066 actions.

Contexte clé :

  • Les attributions font partie de la rémunération habituelle des administrateurs et ne résultent pas d’achats sur le marché libre.
  • L’acquisition des RSU les plus importantes nécessite que Rapp continue à siéger au conseil jusqu’en 2026, ce qui indique une stabilité attendue de son mandat.
  • Aucun instrument dérivé n’a été déclaré et aucune cession n’a eu lieu.

Insider-Aktivitäten: Direktor Edward J. Rapp reichte ein Formular 4 ein, das zwei Aktienzuteilungen vom 10.07.2025 offenlegt. Er erwarb 62.377 Restricted Stock Units (RSUs), die entweder am 10.07.2026 oder am Vorabend der Hauptversammlung 2026 vesten, je nachdem, was früher eintritt, und erhielt zusätzlich 1.601 RSUs anstelle seiner Barvergütung für das zweite Quartal 2025 als Vorsitzender des Prüfungsausschusses, die sofort vesteten. Alle Aktien wurden kostenfrei erworben.

Besitz nach der Transaktion: Rapp hält nun 121.894 Stammaktien direkt (einschließlich 62.377 nicht vesteter RSUs) und 21.172 Aktien indirekt über einen Trust, was seine gesamte wirtschaftliche Beteiligung auf 143.066 Aktien erhöht.

Wichtiger Kontext:

  • Die Zuteilungen sind Teil der regulären Vergütung für Direktoren und keine Käufe am freien Markt.
  • Das Vesting der größeren RSU-Position setzt voraus, dass Rapp bis 2026 im Vorstand bleibt, was auf eine erwartete Stabilität seiner Amtszeit hinweist.
  • Es wurden keine derivativen Wertpapiere gemeldet und keine Veräußerungen vorgenommen.
Positive
  • Director’s ownership increases to 143,066 shares, enhancing alignment with shareholders.
  • 62,377 RSUs vest only with continued service through 2026, supporting board stability.
Negative
  • None.

Insights

TL;DR: Routine RSU grants boost director’s stake; marginally positive signal but not a market-moving event.

The filing reflects standard board compensation rather than discretionary open-market buying. While the addition of 64k RSUs lifts Edward Rapp’s direct holdings to 122k shares and total exposure to roughly 143k, the shares were awarded at no cost and most remain unvested for a year. Such awards reinforce alignment between the director and shareholders and suggest his intention to stay through at least the 2026 annual meeting. However, because the transaction does not involve cash outlay or a change in ownership structure, it is unlikely to materially impact XOS’s valuation or liquidity. Overall impact on the stock is neutral.

Attività degli insider: Il direttore Edward J. Rapp ha presentato un Modulo 4 per comunicare due assegnazioni di azioni effettuate il 10/07/2025. Ha acquisito 62.377 Unità Azionarie Vincolate (RSU) che matureranno alla data anticipata tra il 10/07/2026 o la vigilia dell'assemblea annuale del 2026, e ha ricevuto ulteriori 1.601 RSU in sostituzione del compenso in contanti del secondo trimestre 2025 per la presidenza del Comitato di Revisione, che sono maturate immediatamente. Tutte le azioni sono state acquisite a costo zero.

Possesso post-transazione: Rapp detiene ora 121.894 azioni ordinarie direttamente (incluse 62.377 RSU non ancora maturate) e 21.172 azioni indirettamente tramite un trust, portando la sua partecipazione totale effettiva a 143.066 azioni.

Contesto chiave:

  • Le assegnazioni fanno parte della normale retribuzione dei direttori e non sono acquisti sul mercato aperto.
  • La maturazione del blocco più grande di RSU richiede che Rapp rimanga nel consiglio fino al 2026, indicando una stabilità prevista nella sua permanenza.
  • Non sono stati segnalati strumenti derivati né sono avvenute cessioni.

Actividad de los insiders: El director Edward J. Rapp presentó un Formulario 4 informando sobre dos concesiones de acciones realizadas el 10/07/2025. Adquirió 62,377 Unidades de Acciones Restringidas (RSU) que se consolidarán en la fecha que ocurra primero entre el 10/07/2026 o la víspera de la junta anual de 2026, y recibió 1,601 RSU adicionales en lugar de su remuneración en efectivo del segundo trimestre de 2025 por presidir el Comité de Auditoría, las cuales se consolidaron inmediatamente. Todas las acciones se adquirieron sin costo alguno.

Propiedad después de la transacción: Rapp ahora posee 121,894 acciones comunes directamente (incluyendo 62,377 RSU no consolidadas) y 21,172 acciones indirectamente a través de un fideicomiso, sumando una participación total beneficiaria de 143,066 acciones.

Contexto clave:

  • Las concesiones forman parte de la compensación habitual para directores y no fueron compras en el mercado abierto.
  • La consolidación del bloque mayor de RSU requiere que Rapp continúe en la junta hasta 2026, lo que indica estabilidad esperada en su permanencia.
  • No se reportaron valores derivados ni se realizaron disposiciones.

내부자 활동: 이사 Edward J. Rapp는 2025년 7월 10일에 이루어진 두 건의 주식 부여를 공개하는 Form 4를 제출했습니다. 그는 62,377개의 제한 주식 단위(RSU)를 취득했으며, 이는 2026년 7월 10일 또는 2026년 연례 회의 전날 중 빠른 시점에 베스팅됩니다. 또한 감사위원회 의장으로서 2025년 2분기 현금 보수 대신 추가로 1,601 RSU를 받았으며 이 주식은 즉시 베스팅되었습니다. 모든 주식은 비용 없이 취득되었습니다.

거래 후 소유 현황: Rapp는 현재 직접 보유한 보통주 121,894주(미베스팅 RSU 62,377주 포함)와 신탁을 통해 간접 보유한 21,172주를 보유하여 총 실질 지분이 143,066주입니다.

주요 배경:

  • 이번 부여는 이사 보수의 일환으로 시장에서 매입한 것이 아닙니다.
  • 대규모 RSU 블록의 베스팅은 Rapp가 2026년까지 이사회에 계속 참여해야 하므로 그의 임기 안정성을 시사합니다.
  • 파생 증권 보고는 없었고, 주식 처분도 없었습니다.

Activité des initiés : Le directeur Edward J. Rapp a déposé un formulaire 4 révélant deux attributions d’actions réalisées le 10/07/2025. Il a acquis 62 377 unités d’actions restreintes (RSU) qui seront acquises à la date la plus proche entre le 10/07/2026 ou la veille de l’assemblée générale annuelle 2026, et a reçu 1 601 RSU supplémentaires en lieu et place de sa rémunération en espèces du deuxième trimestre 2025 pour la présidence du comité d’audit, lesquelles ont été acquises immédiatement. Toutes les actions ont été obtenues sans coût.

Possession après la transaction : Rapp détient désormais 121 894 actions ordinaires directement (dont 62 377 RSU non acquises) et 21 172 actions indirectement par le biais d’une fiducie, portant sa participation bénéficiaire totale à 143 066 actions.

Contexte clé :

  • Les attributions font partie de la rémunération habituelle des administrateurs et ne résultent pas d’achats sur le marché libre.
  • L’acquisition des RSU les plus importantes nécessite que Rapp continue à siéger au conseil jusqu’en 2026, ce qui indique une stabilité attendue de son mandat.
  • Aucun instrument dérivé n’a été déclaré et aucune cession n’a eu lieu.

Insider-Aktivitäten: Direktor Edward J. Rapp reichte ein Formular 4 ein, das zwei Aktienzuteilungen vom 10.07.2025 offenlegt. Er erwarb 62.377 Restricted Stock Units (RSUs), die entweder am 10.07.2026 oder am Vorabend der Hauptversammlung 2026 vesten, je nachdem, was früher eintritt, und erhielt zusätzlich 1.601 RSUs anstelle seiner Barvergütung für das zweite Quartal 2025 als Vorsitzender des Prüfungsausschusses, die sofort vesteten. Alle Aktien wurden kostenfrei erworben.

Besitz nach der Transaktion: Rapp hält nun 121.894 Stammaktien direkt (einschließlich 62.377 nicht vesteter RSUs) und 21.172 Aktien indirekt über einen Trust, was seine gesamte wirtschaftliche Beteiligung auf 143.066 Aktien erhöht.

Wichtiger Kontext:

  • Die Zuteilungen sind Teil der regulären Vergütung für Direktoren und keine Käufe am freien Markt.
  • Das Vesting der größeren RSU-Position setzt voraus, dass Rapp bis 2026 im Vorstand bleibt, was auf eine erwartete Stabilität seiner Amtszeit hinweist.
  • Es wurden keine derivativen Wertpapiere gemeldet und keine Veräußerungen vorgenommen.
FALSE000141766300014176632025-07-142025-07-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)July 14, 2025
SANUWAVE Health, Inc.
(Exact name of registrant as specified in its charter)
Nevada000-5298520-1176000
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
11495 Valley View Road,Eden Prairie,Minnesota55344
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code(952)656-1029
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)
Name of each exchange on which
registered
Common stock, par value $0.001 per shareSNWVThe Nasdaq Stock Market LLC

Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
1


Item 2.02              Results of Operations and Financial Condition.

On July 14, 2025, Sanuwave Health, Inc., a Nevada corporation (the “Company”), issued a press release announcing certain preliminary financial results for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01              Financial Statements and Exhibits.
(d)Exhibits.
Exhibit
No.
Description
99.1
Press Release dated July 14, 2025
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SANUWAVE HEALTH, INC.
Dated: July 14, 2025By:/s/ Peter Sorensen
Name:Peter Sorensen
Title:Chief Financial Officer
3

FAQ

How many XOS shares did Director Edward Rapp acquire on 07/10/2025?

He received 62,377 RSUs and 1,601 RSUs, totaling 63,978 shares.

What is Edward Rapp’s total beneficial ownership in XOS (XOS) after the Form 4 transactions?

He now reports 143,066 shares (121,894 directly, 21,172 indirectly via trust).

Do the newly granted RSUs to Edward Rapp vest immediately?

Only the 1,601 RSUs tied to the Audit Committee retainer vested immediately; 62,377 RSUs vest in 2026 or before the 2026 AGM.

Were any XOS shares sold in this Form 4 filing?

No. The filing shows only acquisitions; there were no dispositions.

Did Director Rapp pay cash for the RSUs?

No, the RSUs were awarded at $0 cost as part of board compensation.
Sanuwave Health

NASDAQ:SNWV

SNWV Rankings

SNWV Latest News

SNWV Latest SEC Filings

SNWV Stock Data

283.79M
8.09M
3.86%
26.54%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SUWANEE